Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
The effects of azapeptides on the immunometabolic reprogramming of macrophages
EF 2017-18
Résumé
CD36 is a receptor present on the surface of a great variety of cells. One of its main function is to control energy storage and expenditure by facilitating lipid uptake into cells. On macrophages, specialized cells of our immune system, CD36 is also known to act as an environment sensor. It can detect, for instance, bacterial components or dying cells that must be eliminated by macrophages. The binding of these components to CD36 induces an inflammatory signal in order for our body to fight against aberrant processes such as infection. Macrophages can undertake multiple activity profiles depending on their environment. M1 macrophages promote inflammation, whereas M2 macrophages favour tissue repair by attenuating inflammation. It is now well known that these two types of macrophages are also distinct in their way of producing energy. One of our previous studies have shown that azapeptides have a calming effect on inflammation in mice by binding to CD36. We propose that these azapeptide compounds, by binding to CD36, can force the macrophages to take an energy-producing pathway that would lead them to undertake the M2 profile. Our aims are to validate if azapeptides can actually force this «immunometabolic reprogramming» on macrophages, and to investigate by which mechanism they do so. Because CD36 on macrophages are involved in many pathologic conditions involving a chronic inflammation, the potential to target CD36 is an exciting prospect. The therapeutic effects of azapeptides have already been studied by our group in atherosclerosis, a cardiovascular disease. Age-related degenerative diseases such as Alzheimer's disease are other examples in which targeting CD36 holds promise.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386535
Name
Dorion Marie-France
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The effects of azapeptides on the immunometabolic reprogramming of macrophages
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cd36; Immunometabolism; Macrophage; Oxydative Stress; Pgc-1alpha; Scavenger Receptor
Abstract
CD36 is a receptor present on the surface of a great variety of cells. One of its main function is to control energy storage and expenditure by facilitating lipid uptake into cells. On macrophages, specialized cells of our immune system, CD36 is also known to act as an environment sensor. It can detect, for instance, bacterial components or dying cells that must be eliminated by macrophages. The binding of these components to CD36 induces an inflammatory signal in order for our body to fight against aberrant processes such as infection. Macrophages can undertake multiple activity profiles depending on their environment. M1 macrophages promote inflammation, whereas M2 macrophages favour tissue repair by attenuating inflammation. It is now well known that these two types of macrophages are also distinct in their way of producing energy. One of our previous studies have shown that azapeptides have a calming effect on inflammation in mice by binding to CD36. We propose that these azapeptide compounds, by binding to CD36, can force the macrophages to take an energy-producing pathway that would lead them to undertake the M2 profile. Our aims are to validate if azapeptides can actually force this «immunometabolic reprogramming» on macrophages, and to investigate by which mechanism they do so. Because CD36 on macrophages are involved in many pathologic conditions involving a chronic inflammation, the potential to target CD36 is an exciting prospect. The therapeutic effects of azapeptides have already been studied by our group in atherosclerosis, a cardiovascular disease. Age-related degenerative diseases such as Alzheimer's disease are other examples in which targeting CD36 holds promise.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dorion, Marie-France
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~